This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is a Beat in the Cards for Pfizer (PFE) in Q2 Earnings?
by Zacks Equity Research
While Pfizer, Inc.'s (PFE) new drugs like Ibrance and acquisitions like Hospira are likely to drive sales in Q2, genericization of key drugs, pricing pressure and rising competition will hurt sales.
Biotech Stocks Jul27 Q2 Earnings Roster: BMY, CELG & ALXN
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY), Celgene (CELG) and Alexion Pharma (ALXN) are set to report second-quarter results on Jul 27.
Biogen (BIIB) Tops Q2 Earnings & Sales, Spinraza Sales Up
by Zacks Equity Research
Biogen Inc. (BIIB) surpassed expectations both for earnings and sales in the second quarter of 2017. The MS drugmaker also raised its revenue guidance for 2017 on the back of strong Spinraza sales.
Drug Stocks Q2 Earnings Releases on Jul 26: GILD, VRTX, GSK
by Zacks Equity Research
We have three pharma giants that are set to report second-quarter results on Jul 26. Let's see how things are shaping up for this quarter.
What's in the Cards for Geron (GERN) this Earnings Season?
by Zacks Equity Research
Investors will be looking at Geron's progress with its hematologic myeloid malignancies pipeline candidate, Imetelstat.
Big Pharma Q2 Earnings Releases on Jul 25: LLY, BIIB, AMGN
by Zacks Equity Research
Three pharma giants are set to report second-quarter results on Jul 25. Let's see how things are shaping up for this quarter.
AbbVie Inc's. (ABBV) Q2 Earnings: Disappointment in Store?
by Zacks Equity Research
AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company toward an earnings beat in Q2 despite a negative Earnings ESP posing a threat to the stock.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Coca-Cola, Honeywell, Crown Castle and WEC Energy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Coca-Cola, Honeywell, Crown Castle and WEC Energy
J&J Brightens Outlook: Healthcare ETFs in Focus
by Sweta Killa
Johnson & Johnson continued its long streak of earnings beat and offered an upbeat outlook for the full year. However, it lagged our revenue estimate.
Company News for July 19, 2017
by Zacks Equity Research
Companies in the News are: JNJ,BAC,UNH,CMG
Gilead's HCV Portfolio Receives a Boost With Vosevi Approval
by Zacks Equity Research
Gilead's (GILD) HCV portfolio received a boost with the FDA's approval of its once-daily HCV regimen, Vosevi.
Wall Street banks and other household brands report earnings results.
by Zacks Equity Research
Wall Street banks and other household brands report earnings results.
J&J (JNJ) Beats on Q2 Earnings, Lags Sales, Ups 2017 View
by Zacks Equity Research
Johnson & Johnson (JNJ) reported mixed second-quarter 2017 results. While earnings beat expectations, sales missed the same.
Novartis Tops Q2 Earnings, Sandoz Faces Pricing Pressure
by Zacks Equity Research
Novartis AG (NVS) reported second-quarter 2017 core earnings of $1.22 per share, beating the Zacks Consensus Estimate of $1.16 but the recorded figure was a penny lower than the year-ago figure of $1.23.
Q2 Earnings Reports Hit the Tape: GS, BAC, JNJ, LMT & UNH
by Mark Vickery
Goldman Sachs (GS) beat estimates on both top and bottom lines, but shares are selling off following this earnings report on drastically lower fixed income revenues.
J&J (JNJ) Beats on Q2 Earnings, Ups 2017 EPS & Sales View
by Kinjel Shah
Johnson & Johnson (JNJ) reported mixed second-quarter 2017 results, with earnings beating expectations while sales slightly missing the same.
Earnings All Stars with Perfect Charts
by Tracey Ryniec
Don't just settle for good earnings surprise records when you can have great with these 5 companies who report this week.
4 Sell-Ranked Drug Stocks to Avoid Ahead of Q2 Earnings
by Arpita Dutt
Here is a look at four drug stocks including Anika (ANIK) with a Sell Rank and negative earnings ESP that should be avoided ahead of earnings.
J&J (JNJ) Gets FDA Nod for Psoriasis Drug -- Guselkumab
by Zacks Equity Research
Johnson & Johnson (JNJ), a healthcare bellwether, announced that the FDA has approved its pipeline candidate guselkumab for the treatment of moderate-to-severe plaque psoriasis. The drug will be marketed by the trade name of Tremfya.
Abbott Partners Bigfoot Biomedical to Expand in Diabetics
by Zacks Equity Research
Illinois-based global medical device company Abbott Laboratories (ABT) partnered with Bigfoot Biomedical to solidify its footprint in the rapidly growing diabetes therapeutics market.
Amgen's Myeloma Drug Improves Overall Survival in Phase III
by Zacks Equity Research
Biotech major, Amgen, Inc. (AMGN) announced final data from the phase III ASPIRE study, which showed that a combination regimen of its drug, Kyprolis, significantly improved overall survival (OS) in patients with relapsed multiple myeloma.
J&J (JNJ) to Commence Pharma Q2 Earnings Season: What's Up?
by Zacks Equity Research
Johnson & Johnson (JNJ), a healthcare bellwether, will report second-quarter 2017 results on Jul 18.
Here's Why Arena Pharmaceuticals (ARNA) Stock is Skyrocketing Today
by Madeleine Johnson
On Tuesday, shares of biopharmaceutical company Arena Pharmaceuticals (ARNA) are skyrocketing, up about 41% to $26.10 per share in afternoon trading after it reported positive mid-stage trial results for one of its drugs.
Arena's Ralinepag Positive in Phase II PAH Study, Shares Up
by Zacks Equity Research
Arena Pharmaceuticals, Inc. (ARNA) shares surged 41.3% in after-market trading on Monday after its phase II study evaluating its key pipeline candidate, ralinepag, in pulmonary arterial hypertension, met the primary endpoint.
Novartis' Cosentyx Superior to Stelara in Psoriasis Study
by Zacks Equity Research
Novartis' (NVS) psoriasis drug Cosentyx got a label update from the Committee for Medicinal Products for Human Use (CHMP) in the EU,